Cell culture products and methods for making cell culture products

WO2026234267A1PCT designated stage Publication Date: 2026-11-12GOOD DOG FOOD LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063488
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

Smart Images

  • Figure EP2026063488_12112026_PF_FP_ABST
    Figure EP2026063488_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A process is provided to produce an animal cell culture product. The process comprises the steps of culturing animal cells in suspension within a liquid cell culture medium under conditions that promote proliferation until a required cell concentration is attained. A flocculating agent is added to the cell culture suspension to initiate flocculation of the cultured animal cells, so as to form an aggregated cell culture product. The aggregated cell culture product is recovered by removing the liquid cell culture medium, suitably without the need for centrifugation. Cell culture products may be used in production of cultivated meat for human or animal consumption.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CELL CULTURE PRODUCTS AND METHODS FOR MAKING CELL CULTURE PRODUCTS

[0002] FIELD OF THE INVENTION

[0003] The present application is directed to processes and methods for use in the manufacture of cell culture products. The present application is also directed to cultivated meat products obtained by the disclosed processes and methods.

[0004] BACKGROUND TO THE INVENTION

[0005] A significant impediment to commercial viability in the field of laboratory-generated cell culture products remains the suboptimal efficiency of biomass harvesting from suspension bioreactor cultures. While adherent culture systems facilitate straightforward cell collection through enzymatic or mechanical detachment, suspension-based culture systems — despite their far superior scalability and reduced operational costs — continue to encounter numerous technical hurdles limiting downstream recovery efficiency. These challenges include cellular damage during separation processes, incomplete biomass recovery due to inefficient clarification methods, loss of cellular viability during concentration steps, and difficulties maintaining product quality throughout harvesting operations.

[0006] Current harvesting technologies frequently fail to accommodate the delicate balance between efficient biomass collection and preservation of cellular structural characteristics, resulting in diminished properties of the final product. The absence of standardized harvesting parameters across different cell types further complicates the development of universally applicable recovery protocols, necessitating resource-intensive optimization for each production system to maximize economically viable biomass yield.

[0007] In the field of cultivated meat production, a challenge to efficient continuous biomass production has been the need to utilise centrifugation for efficient biomass harvesting. Centrifugation adds process complexity as well as considerable capital and energy cost, whilst also slowing down process flows. Hence, it would be desirable to provide alternative separation technologies that do not compromise product quality.

[0008] The use of biopolymer-based flocculation techniques has been investigated in the fields of wastewater treatment (Renault et al. (2009) European Polymer Journal, Volume 45, Issue 5, p1337-1348), monoclonal antibody recovery (Riske et al. (2007). J Biotechnol. 2007 Mar 10; 128(4):813-23) and also for harvesting microalgal biomass (Elcik et al. (2023) Separations, 10(9), 507). However, animal cell suspension cultures provide a unique and complex challenge forsuch approaches which have not yet been successfully demonstrated for the production of cell culture products or specifically for cultivated meat products.

[0009] These and other uses, features and advantages of the invention should be apparent to those skilled in the art from the teachings provided herein.

[0010] SUMMARY OF THE INVENTION

[0011] In a first aspect the invention provides a process for the production of an animal cell culture product, the process comprising the steps of:

[0012] a. culturing animal cells in suspension within a liquid cell culture medium under conditions that promote proliferation until a required cell concentration is attained; b. adding a flocculating agent to the cell culture suspension to initiate flocculation of the cultured animal cells, so as to form an aggregated cell culture product; and c. recovering the aggregated cell culture product by removing the liquid cell culture medium.

[0013] Suitably, the animal cell culture product is for use in the production of cultivated meat or other food products that may be for human or animal consumption.

[0014] In a second aspect provides for a cell culture product obtainable by a process as described herein. A third aspect provides a cell culture product comprising animal cells, extracellular secreted protein and a polymer having a high cationic charge density.

[0015] A fourth aspect provides for a consumable cultivated meat product comprising the cell culture product.

[0016] A fifth aspect the use of a polymer having a high cationic charge density as a flocculating agent in a process for harvesting biomass from a suspension culture of animal cells.

[0017] Within the scope of this application it is expressly intended that the various aspects, embodiments, examples and alternatives set out in the preceding paragraphs, in the claims and / or in the following description and drawings, and in particular the individual features thereof, may be taken independently or in any combination. That is, all embodiments and / or features of any embodiment can be combined in any way and / or combination, unless such features are incompatible.BRIEF DESCRIPTION OF THE DRAWINGS

[0018] One or more embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which:

[0019] Figure 1 shows a flow diagram according to one embodiment of a process of the present invention.

[0020] Figure 2 shows a graphical representation of yield of cell culture products obtained by methods using a flocculating agent that comprises a chitosan. A: cell culture product (CCP) yield in g / L for wet biomass harvested from a cell suspension of 106cells / mL using increasing concentrations (w / v) of crustacean chitosan. B: CCP Average yield in g / L for wet biomass harvested from cell suspensions at a density of 0.9 x 106cells / mL using vegan chitosan. C: CCP yield in g / L for wet biomass harvested from a cell suspension of 44.6 x 106cells / mL using vegan chitosan. D: flocculation assessment at various pH levels using vegan chitosan. ECCP yield at various pH using vegan chitosan (1.25 x 106cells / mL).

[0021] Figure 3 shows pictorial and graphical representations of enhancement of flocculation by chitosan enhancers. A: dextran sulfate concentrations (106cells / mL). B: carboxymethylcellulose (CMC) concentrations (0.75 x 106cells / mL). C: calcium chloride concentrations (6.96 x 106cells / mL). D: chitosan + dextran sulfate 0.3mg / mL, 2.76 x 106cells / mL E: chitosan + CMC 70mg / L, 2.76 x 106cells / mL. F: chitosan + calcium chloride 0.1 mM, 2.76 x 106cells / mL. G: Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS PAGE) of protein content before (-) and after (+) harvesting by chitosan with CMC (140mg / L) at 1.2-1.8 x 106cells / mL. H: protein analysis of blot shown in G, analysed in Imaged. **p<0.001.

[0022] DETAILED DESCRIPTION OF THE INVENTION

[0023] All references cited herein are incorporated by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0024] As used herein, the term ‘comprising’ means any of the recited elements are necessarily included and other elements may optionally be included as well. ‘Consisting essentially of’ means any recited elements are necessarily included, elements that would materially affect the basic and novel characteristics of the listed elements are excluded, and other elements may optionally be included. ‘Consisting of’ means that all elements other than those listed are excluded. Embodiments defined by each of these terms are within the scope of this invention.

[0025] As used herein, the term ‘substantially’ refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. The exact allowable degreeof deviation from absolute completeness may in some cases depend on the specific context, as would be understood to the person of skill in the art. However, in general terms the nearness of conformity to the absolute will be such as to have the same overall result - e.g. functional equivalence - as if total conformity were achieved.

[0026] The term ‘cultivated meat’ refers to meat grown in a laboratory from animal cells. Cultivated meat, also known as but not limited to ‘cultured meat’, ‘laboratory-grown meat’, ‘cell-based meat’, ‘slaughter-free meat’, ‘clean meat’ or ‘in vitro meat’ can be grown from a wide variety of animal species by means of cell culture. Animal species used to produce cultivated meat includes mammals such as cow, pig, goat, sheep, deer, and even exotic mammals such as kangaroo, elk, etc; avian cells such as poultry including chicken, duck, goose, turkey, partridge, grouse, pigeon, guinea fowl, ostrich, quail etc.; seafood fish such as salmon, trout, tuna, hake, halibut, haddock, cod, tilapia, atlantic croaker, swordfish or coley; crustaceans including prawn, shrimp, lobster, crab, crawfish etc.; or even reptiles such as turtle, crocodile, alligator, snake etc; molluscs, such as octopus, squid, abalone, cuttlefish or bivalves including oyster, mussel, scallop, clam; or insects. Typically, cultivated meat comprises animal cells and animal protein. Animal protein, which may be associated with animal cells, may be in the form of extracellular matrix and / or secreted proteins. In embodiments, the cultivated meat comprises mammalian or avian cells. Suitably, the cells used for producing cultivated meat include stem cells. In some embodiments, the cells are primary stem cells, self-renewing stem cells, embryonic stem cells, pluripotent stem cells, induced pluripotent stem cells, or transdifferentiated pluripotent stem cells. In some embodiments, the cells are spontaneously immortalised cell lines. In some embodiments, the cells are treated to induce pluripotency. In some embodiments, the cells are genetically modified. In some embodiments, the cells may be derived from various source organisms, including but not limited to bovine, porcine, ovine, and galliform species, and can be isolated, spontaneously immortalised, expanded, and differentiated under controlled conditions.

[0027] In specific embodiments of the invention the cultivated meat comprises mammalian or avian immortalised fibroblasts.

[0028] In alternative embodiments of the invention the cultivated meat comprises mammalian or avian cells of myogenic origin, including skeletal muscle cells or precursors thereof. Suitably, cells having or predisposed towards a myogenic lineage may be cultured in combination with adipocytes, fibroblasts, or endothelial cells to more accurately recapitulate the structure, flavour or composition of conventional meat products. In embodiments where the cells are myogenic cells, they may be stem cells or precursor stells programmed to become muscle, or muscle-like cells. In some embodiments, the myogenic cells are natively myogenic, e.g. myoblasts. Natively myogenic cells include, but are not limited to, myoblasts, myocytes, satellite cells, side population cells, muscle derived stem cells, mesenchymal stem cells, myogenic pericytes, or mesoangioblasts. In someembodiments, the cells are non-myogenic, and such non-myogenic cells can be programmed to exhibit a myogenic phenotype.

[0029] Natively myogenic cells can be grown to form multicellular meat substitutes through a multi-stage bioprocess that involves cell isolation, expansion, differentiation, and tissue formation. The process typically begins with the isolation of various myogenic cell types, as described above, from donor animal tissue. Satellite cells (also called ‘myosatellite cells’), which reside beneath the basal lamina of muscle fibers, represent the primary adult multipotent stem cell population for muscle regeneration and are commonly utilized due to their robust proliferative capacity and commitment to the myogenic lineage. When activated, these cells proliferate as myoblasts before differentiating. Myoblasts are proliferative precursor cells that can be expanded in vitro under appropriate growth conditions. Upon reaching sufficient density and receiving differentiation cues, myoblasts withdraw from the cell cycle, align, and fuse to form multinucleated myotubes, which further mature into functional myocytes (referred to herein as ‘muscle cells’).

[0030] The term ‘cell culture,’ refers to a collection of cells grown outside of their natural environment, typically in a laboratory setting. Cell cultures may be adherent cultures, to static surfaces or to suspended microcarriers, or microcarrier-free suspension cultures. Adherent cell cultures involve cells that grow attached to a surface, requiring a substrate for proliferation and survival. In static adherent culture, cells are typically cultured in petri dishes or cell culture flasks often coated with a substrate such as gelatin, collagen, or extracellular matrix proteins. In suspended adherent culture, cells are typically cultured adherent to microcarriers of different nature (collagen, gelatin, dextran sulfate, plastic, etc), being suspended in agitated flasks and bioreactors. In contrast, microcarrier-free suspension cultures allow cells to grow freely in a cell culture medium. Unlike adherent cells that attach to a substrate, suspension cells freely float in the medium, either as single cell suspension or as natural aggregates, typically in bioreactors or flasks which often include agitation systems. The term ‘cell culture’ encompasses cultures obtained from different cell types including animal cells.

[0031] In embodiments of the present invention, animal cells are grown in suspension culture within one or more bioreactors.

[0032] The terms ‘cell culture medium’ and ‘culture medium’ refer to a nutrient solution used for growing cell cultures. A cell culture medium is composed of a number of ingredients and these ingredients vary from one culture medium to another. A cell culture medium may be a complete formulation, i.e. , a cell culture medium that requires no supplementation to culture cells, may be an incomplete formulation, i.e., a cell culture medium that requires supplementation or may be a supplement that is used to supplement an incomplete formulation or in the case of a complete formulation, may improve culture or culture results. A cell culture medium may include various factors necessary for cell growth, and maintenance of the cellular environment. For example, a typical nutrient solution may include a basal media formulation, various supplements depending on the cell type and,occasionally, antibiotics. Suitable basal media may include or be based upon Dulbecco’s modified Eagle’s medium (DMEM) or basal medium Eagle (BME). In some embodiments, a nutrient solution may include at least one component from one or more of the following categories: 1) an energy source, usually in the form of a carbohydrate such as glucose; 2) all essential amino acids, and usually the basic set of twenty amino acids plus cystine; 3) micronutrients that include vitamins and / or other organic compounds; 4) free fatty acids; and 5) trace elements. Trace elements are defined as inorganic compounds or naturally occurring elements that are typically required at very low concentrations, usually in the micromolar range. The nutrient solution in some embodiments may optionally be supplemented with one or more components such as hormones, carriers and growth factors as, for example, insulin, transferrin, transforming growth factor beta (TGF-beta), activin, interleukins, fibroblast growth factors (FGFs), insulin like growth factors (IGFs), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF) and / or epidermal growth factor (EGF); salts and buffers as, for example, calcium, magnesium, and phosphate; nucleosides and bases such as, for example, adenosine and thymidine, hypoxanthine; and protein and tissue hydrolysates. In general, any suitable cell culture medium may be used. The medium may comprise of serum, e.g. foetal bovine serum, calf serum or an equivalent the like. Alternatively, in specific embodiments the medium may be entirely serum free, animal protein free, or protein free. In some embodiments, the medium is substantially protein free. In such embodiments, the cells comprised within the cell culture may naturally or be genetically modified to secrete one or more components such as hormones and / or growth factors into the protein free medium. A serum free or protein free medium may further comprise a biogenic amine such a monoamine or a polyamine, including an ethanolamine, putrescine, spermidine and / or spermine.

[0033] In an embodiment, the cell culture medium is a suspension culture medium. Suspension culture media are known in the art. Typically, suspension media include a carbon source, a nitrogen source, inorganic salts, vitamins, trace elements, buffering salts and / or surfactants. Depending on the type of cells being grown, the suspension medium may also include serum, growth regulators and / or antibiotics. Alternatively, the suspension medium may be entirely serum-free, growth factor free, or even protein-free.

[0034] The term ‘flocculation’ refers to the process by which colloids or fine particles in liquid suspension aggregate into larger particles. These larger particles suitably grow via aggregation to a size that enables precipitative separation from the liquid media. Flocculation has been used as an alternative separation technology to enhance centrifugal clarification throughput and centrate quality, thereby improving the downstream filtration operations. While chemical flocculation is quite effective in agglomerating cellular debris and cellular contaminants (host cell proteins and DNA), the resulting flocculated suspension is generally not easily separable by ordinary filtration methods without the use of a centrifuge prior to filtration.A ‘flocculating agent’, or ‘flocculant’, as used herein is an agent that facilitates precipitation of particles in suspension, such as cells, cell debris and proteins. The process of flocculation occurs via the interaction between the surface charges on the cell or protein, and charges on the flocculant. In specific embodiments of the present invention, the flocculant comprises polymer, such as a biopolymer, that has high cationic charge density. Suitably, the biopolymer may comprise a plurality of amino groups, or even a plurality of quaternised amines. The flocculant creates insoluble complexes with the particles in suspension and subsequently bridges adjacent insoluble complexes either by residual charge interaction or through hydrophobic patches on the complexes to form larger clusters. Suitable polymeric flocculants include, but are not limited to, polyethyleneimine (PEI), and polydiallyldimethylammonium chloride (polyDADMAC). In embodiments, biopolymer-based flocculants may include, but are not limited to, chitosan, cellulose derivatives, starch-based polymers, as well as inulin. In some embodiments, the flocculation agent comprises a biopolymer or a polysaccharide. In a specific embodiment the biopolymer flocculant is a chitosan or a variant or derivative thereof.

[0035] Chitosan is a cationic linear copolymer of beta (1-4) linked D-glucosamine and N acetyl-D-glucosamine. It is produced by the deacetylation of chitin, a naturally occurring biopolymer. Chitosans exist in several types or variants, which differ based on characteristics such as organic source, degree of deacetylation, molecular weight, and modifications. Some of the known sources of chitosan include: crustacean chitosan (e.g., from crab, shrimp, lobster shells), fungal chitosan (e.g., from fungi cell walls), insect chitosan (e.g., from insect exoskeletons). Chitosan may be classified based on degree of deacetylation (DD): low DD chitosan (typically 55-70%), medium DD chitosan (typically 70-85%), high DD chitosan (typically 85-100%). Chitosan may be classified based on molecular weight: low molecular weight chitosan (LMW, <50 kDa), medium molecular weight chitosan (MMW, 50-150 kDa), high molecular weight chitosan (HMW, >150 kDa). Chitosan may be chemically modified to produce a range of chitosan derivatives. Examples include but are not limited to: carboxymethyl chitosan, trimethyl chitosan, N-succinyl chitosan, thiolated chitosan, quaternised chitosan, chitosan oligosaccharides, PEGylated chitosan, glycol chitosan. Chitosan may also be physically modified to produce a range of derivates. Examples of physical modifications include but are not limited to chitosan nanoparticles, chitosan microparticles, chitosan hydrogels, chitosan films and membranes, chitosan fibres, chitosan sponges. As cultivated meat is typically focused on eliminating or reducing animal-origin ingredients, in specific embodiments vegan chitosan produced from fungi may be suitable for the production of cultivated meat.

[0036] In use as a flocculant, in embodiments of the invention, a cationic polymer - such as a biopolymer, e.g. chitosan - may be added to a cellular suspension to initiate biomass harvesting via induction of precipitative flocculation without the need for centrifugation.In some embodiments, the concentration of a cationic polymer or biopolymer, such as a chitosan, is selected from at least around: 0.01%w / v; 0.02%w / v, 0.05%w / v; 0.1%w / v; 0.2%w / v; 0.5%w / v; 0.7%w / v; 1%w / v; 1.2%w / v; 1.5%w / v; 1.7%w / v; 2%w / v; 2.2%w / v; 2.5%w / v; 2.7%w / v; or 3%w / v in the cell culture medium. In certain embodiments the concentration of the cationic biopolymer, such as a chitosan, is selected from at most around: %w / v; 2.7%w / v; 2.5%w / v; 2.2%w / v; 2%w / v; 1.7%w / v; 1.5%w / v; 1.2%w / v; 1%w / v; 0.7%w / v; 0.5%w / v or 0.02%w / v in the cell culture medium. The concentration may be adjusted depending on the choice of medium and the progress of flocculation. For example, the concentration may begin at a low initial concentration and increased to an optimum value as the rate of flocculation increases. Typically, the concentration of cationic polymer or biopolymer, such as a chitosan, that is added to induce flocculation will be between around 0.02%w / v and 2%w / v in the cell culture medium.

[0037] The process of flocculation may be further assisted by the addition of one or more flocculation aids or enhancer agents. In accordance with an embodiment of the invention one or more flocculation enhancer agents may be added before, during or after addition of the primary flocculant - e.g. a chitosan. Suitable flocculation enhancing agents may be selected from, but are not limited to: dextran sulfate; carboxymethylcellulose (CMC); calcium chloride; polyethylene glycol (PEG); polyethylene oxide (PEO); xanthan gum; alginate and / or citrate. Due to the chemical properties of chitosans, such as high cationic density, it is possible to combine a chitosan with other reagents such as one or more flocculation enhancers. In some embodiments, the concentration of the flocculation enhancer is 0.28 to 140 mg / Lfor CMC, 30 to 300 mg / L for dextran sulfate or 0.1-1 mM calcium chloride in the cell culture medium. In specific embodiments of the invention the flocculation enhancer comprises CMC that is present at a concentration of at least 0.05 mg / L; 0.1 mg / L; 0.2 mg / L; 0.5 mg / L; 1 mg / L; or 10 mg / L. In further embodiments of the invention the flocculation enhancer comprises dextran sulfate that is present at a concentration of at least 1 mg / L; 5 mg / L; 10 mg / L; 20 mg / L; 50 mg / L; or 100 mg / L. In other embodiments of the invention the flocculation enhancer comprises calcium chloride that is present at a concentration of at least 0.01 mM; 0.05 mM; 0.1 mM; 0.5 mM.

[0038] In embodiments of the invention, the flocculating agent and flocculation enhancer may be added to the cell culture medium simultaneously or successively. In some embodiments, the flocculation agent and flocculation enhancer are premixed to form a flocculation composition. A single or a combination of flocculation enhancers may be used within the flocculation composition.

[0039] The term ‘cell culture product’ refers to the mass of cells, proteins and other associated cellular or cell derived components in the cell culture medium that are flocculated by the flocculation agent. The cell culture product may be in the form of a pellet, a mass or an agglomerate of cells and associated proteinaceous material. In embodiments of the present invention that utilise protein free cell culture media, an advantage of the cell harvesting approach is that it allows for recovery ofmost if not substantially all of the secreted protein content of the cell culture in addition to the cellular biomass.

[0040] The term ‘harvesting’ refers to the process of collecting cells or the cell culture products from the culture system after a period of growth or production. In some embodiments, the cultivated meat of the disclosure is harvested from a cell growth apparatus, for example, from a bioreactor.

[0041] The term ‘bioreactor,’ as used herein, refers to any manufactured or engineered device or system that supports a biologically active environment. In some instances, a bioreactor is a vessel in which a cell culture process is carried out which involves organisms or biochemically active substances derived from such organisms. Such a process may be either aerobic or anaerobic. Commonly used bioreactors are typically cylindrical, ranging in size from litres to cubic meters, and are often made of stainless steel. In some embodiments described herein, a bioreactor is made of a material other than steel, such as a polymer or glass, and is disposable or single use. It is contemplated that the total volume of a bioreactor may be any volume ranging from at least 100 millilitres, suitably at least 1 litre; to up to at most 10,000 litres, at most 20,000 litres, at most 50,000 litres, or up to 100,000 litres or more, depending on a particular process. Multiple vessels may be comprised within an overall bioreactor system. In particular embodiments of the invention, growth and proliferation of cultured cells within suspension may occur within a first bioreactor vessel, whereas biomass harvesting may occur in a second harvesting vessel that is separate from the first and in fluid communication therewith.

[0042] According to a specific embodiment, a multi-vessel bioreactor system may enable substantially continuous operation through synchronized staging of cell culture processes. In such configurations, a first bioreactor vessel maintains optimal conditions for animal cell growth and proliferation in suspension while simultaneously and continuously transferring a portion of the cellcontaining medium to a second harvesting vessel through a regulated fluid communication conduit. This arrangement allows the harvesting process to occur independently of the growth phase, as the second vessel incorporates the specialized mechanisms for biomass separation, concentration, and collection as described herein without disrupting the ongoing cultivation in the first vessel. The system may further incorporate automated feedback controls that monitor cell density in the first vessel and regulate the transfer rate to the second vessel, thereby maintaining ideal growth conditions in the first vessel while ensuring efficient biomass recovery in the harvesting vessel. This separation of functions between growth and harvesting vessels eliminates traditional batch processing limitations, as the primary vessel never requires a complete operational shutdown for harvesting procedures, thus maximizing production efficiency, reducing downtime, and allowing for consistent biomass quality through standardized harvesting conditions that operate independently from the variability inherent in different growth phases.

[0043] The term ‘consumable’ in the context of the cultivated meat of the disclosure refers to an edible product or a product suitable for consumption as a foodstuff. The consumption may be by humansor animals. The term ‘consumable’ encompasses raw or uncooked cultivated meat as well as partially or fully cooked cultivated meat. A consumable may include cell culture products that are prepared to be used as ingredients for other consumable products, such as for the purposes of bulking or improving or increasing protein content. Hence, a consumable need not be in the most optimal form for consumption in its own right, but may be in the form of a cooked or uncooked protein rich cell culture product that can be incorporated into other foodstuffs. In specific embodiments of the invention the consumable is a cultivated meat, such as cultivated chicken, to be used as an ingredient for food products for human consumption or for a pet food product, such as a food suitable for dogs or cats.

[0044] According to one embodiment of the present invention, a process for harvesting of cell culture products (e.g. biomass) comprised within a suspension culture of animal cells is shown in the flow chart of Figure 1. The process 100 includes a first step 101 of culturing animal cells that are to be comprised within the cell culture product until a predetermined cell concentration is achieved. The predetermined cell concentration may be at least 1 x 106cells per millilitre (cells / ml), at least 5 x 106cells / ml, at least 10 x 106cells / ml, at least 20 x 106cells / ml, at least 50 x 106cells / ml, at least 100 x 106cells / ml, or greater than 100 x 106cells / ml,. In specific embodiments predetermined cell concentration may be determined according to mode of operation, such as i) in batch mode VCCs of 1-3 x106cells / ml are desired; ii) in fed-batch mode VCCs of 2-10 x106cells / m are desired; iii) in perfusion mode VCCs of 10-100 x106cells / ml are desired.

[0045] Culturing of cells will typically occur within a suitable bioreactor vessel. Separately, a stock concentration of a flocculation composition, comprising a flocculating agent with or without one or more flocculation enhancing agents, is prepared 102. Preparation of the stock composition comprises dissolution of flocculating agent with or without one or more flocculation enhancing agents within a suitable solvent or diluent liquid. A flocculation step 103 is initiated at the point when harvest of the cell culture products is desired by adding the flocculation composition to the suspension culture of animal cells. The flocculation step may occur within the bioreactor vessel or some or all of the cell culture may be transferred via a fluid conduit to a second biomass harvesting vessel, thereby allowing the primary bioreactor vessel to continue cell culture proliferation without interruption. The flocculation step 103 may comprise some gentle mixing / agitation to facilitate the distribution of the flocculation composition throughout the suspension and also to encourage the process of flocculation. For particular flocculation compositions, such as those comprising a cationic polymer such as a chitosan, the pH during flocculation may be below neutral, suitably below around pH 7, typically around pH 6.5, optionally not less than around pH 5. Following the flocculation step 103, supernatant that is substantially free of cell culture product may be removed in a decanting step 104. It is of significant advantage that the decanting step 104 does not require centrifugation in order to ensure sufficient yield of cell culture product. Discarded supernatant may be purified and recycled as needed. The aggregated cell culture product may be recovered andsubjected to post-processing 105. Post-processing 105 may comprise additional steps of dewatering, pasteurisation, preservation or further onward processing to create consumable products such as cultivated meat for human or animal consumption.

[0046] In specific embodiments, the present invention provides for a cell culture product comprised of animal cells, extracellular secreted protein and polymer, such as a biopolymer, that has high cationic charge density. The cell culture product may be in the form of a heterogeneous agglomerate, such as a cellular paste. In embodiments, the cell culture product may comprise solids content of at least 5% wt, at least 10%wt, at least 15 %wt, at least 20%wt, suitably at least 25%wt.

[0047] Extracellular matrix components, including proteoglycans and structural glycoproteins, may contribute to formation of a supporting scaffold throughout the harvested material, leading to certain cohesive properties. Where the cationic polymer I biopolymer comprises a chitosan, the cell culture product is comprised of a heterogeneous cellular agglomerate that also comprises a chitosan. As mentioned, the chitosan may be of animal (e.g. crustacean) or non-animal (e.g. fungal) origin.

[0048] According to a further embodiment of the present invention, there is provided a consumable cultivated meat product that comprises a harvested cell culture product that is comprised of a heterogeneous cellular agglomerate of animal derived cells and also a polymer, such as a biopolymer, that has high cationic charge density. Suitably the polymer is selected from: a chitosan, or a derivative thereof; a cellulose derivative; a starch-based polymers; or inulin. In embodiments, the consumable cultivated meat product is comprised within or may be used in the preparation of any one of the following non-limiting list of meat-based products:

[0049] a. Structured meat products (burgers, patties, nuggets, strips)

[0050] b. Emulsified meat products (hot dogs, sausages, bologna, mortadella)

[0051] c. Cured meat products (bacon, ham, pastrami, prosciutto)

[0052] d. Minced meat products (ground meat for tacos, pasta sauce, chili)

[0053] e. Whole-cut analogues (steak, chicken breast, pork chop replicas)

[0054] f. Meat-filled dumplings and pastries (wontons, ravioli, empanadas, sausage rolls) g. Dried meat products (jerky, biltong, meat snack sticks)

[0055] h. Smoked meat products (ribs, brisket, pulled pork)

[0056] i. Blended hybrid products (conventional / cultivated meat blends)

[0057] j. Ready-to-eat meal components (pre-cooked strips for salads, sandwiches)k. Freeze-dried meat products (camping / emergency food supplies)

[0058] l. Sous-vide prepared meat products (pre-cooked vacuum-sealed meats)

[0059] m. Marinated meat products (kebabs, fajita strips, satay)

[0060] n. Breaded and coated meat products (schnitzels, cordon bleu)

[0061] o. Stuffed meat products (roulades, meat-stuffed vegetables)

[0062] p. Meat spreads and pates (liverwurst analogues, terrines)

[0063] q. Seasoned meat crumbles (taco filling, pizza topping)

[0064] r. Restructured meat products (ham rolls, deli slices)

[0065] s. Meat-based ingredient preparations (flavour bases, culinary stocks)

[0066] t. Shelf-stable meat products (canned meat, ambient-stable pouches)

[0067] In embodiments, the consumable cultivated meat product is comprised within or may be used in the preparation of any one of the following non-limiting list of meat-based products intended for animal consumption:

[0068] i. Wet canned pet foods (chunks in gravy, pates, loaves)

[0069] ii. Freeze-dried complete pet meals (rehydratable complete nutrition)

[0070] iii. Premium protein kibble coatings (palatability enhancers)

[0071] iv. Dried meat treats and chews (jerky strips, training rewards)

[0072] v. Frozen raw diet components (complete prey model portions)

[0073] vi. Therapeutic veterinary diet proteins (hypoallergenic formulations)

[0074] vii. Soft-moist pet treats (semi-moist nuggets, meat rolls)

[0075] viii. Long-lasting dental chews (structured protein matrices)

[0076] ix. Refrigerated fresh pet foods (meat-based prepared meals)

[0077] x. Specialized life-stage formulations (puppy / kitten growth formulas)

[0078] xi. Protein-enriched supplement toppers (meal enhancers)

[0079] xii. Liquid nutritional supplements (protein hydrolysates)

[0080] xiii. Species-specific exotic proteins (novel protein allergen alternatives)

[0081] xiv. Textured meat inclusions for premium dry foodsxv. Meat-based pill pockets (medication delivery vehicles)

[0082] xvi. Shelf-stable pouched pet foods (retort-processed meals)

[0083] xvii. Zoo animal specialty feeds (carnivore diet components)

[0084] xviii. Aquaculture feed ingredients (high-protein feed components)

[0085] xix. Reptile and exotic pet food formulations (whole-prey analogues)

[0086] xx. Enrichment treat dispensers (fillable training devices)

[0087] xxi. Recovery diets for hospitalized animals (high-calorie nutrition)

[0088] xxii. Breeding stock specialty nutrition (fertility enhancement feeds)

[0089] xxiii. Performance animal supplements (working dog energy products)

[0090] xxiv. Wildlife rehabilitation feed components (rehabilitation nutrition)

[0091] In further embodiments, the recovered cell culture product may be used as a component of a bioink composition for use in additive manufacture of structured food products, including 3D printed food products and, in particular, meat mimetic products. The cell culture product described herein, which may comprise animal cells, extracellular secreted protein and a polymer such as a biopolymer having high cationic charge density, and which may be provided in the form of a heterogeneous cellular agglomerate or cellular paste, is particularly suitable for incorporation into a printable food composition. Such a bio-ink composition may comprise the cell culture product in combination with one or more additional edible components, including plant-derived proteins, structuring agents, binders, flavouring agents, nutritional components, texturising agents and / or further food-grade hydrocolloids, so as to provide a composition having rheological properties suitable for extrusion, deposition or shaping during 3D printing. The use of the cell culture product as a bio-ink component enables the preparation of structured cultivated meat-based food products in which flavour, texture, nutritional profile and spatial distribution of animal-derived and plant-derived components can be tailored. In particular embodiments, the bio-ink composition may be used to produce 3D printed meat mimetics having defined architecture, texture, mouthfeel and nutritional content, optionally by combining 3D printing with one or more further manufacturing techniques such as bioprinting or electrospinning. The resulting printed food products may therefore provide structured cultivated meat-based products having desirable sensory qualities and consumer-acceptable flavour and texture characteristics.

[0092] The invention is further exemplified with reference to the following non-limiting examples.EXAMPLES

[0093] Example 1 - High charge density cationic biopolymers can be used as flocculant for animal cell culture products

[0094] Current methods for harvesting cell culture products (CCPs) are mainly based on separation of the cells and their supernatant through centrifugation. Centrifugation can be a lengthy process, as well as costly, due to the heavy and expensive eguipment necessary to handle large volumes. To optimise the production process of cultivated meat and the harvest of CCPs, the current application focuses on harvesting through flocculation.

[0095] To investigate whether a high charge density cationic biopolymer, such as a chitosan, could also be used as a flocculant in animal cell culture, firstly a concentration range was applied to identify the optimal concentration (Figure 2A). Increasing concentrations of chitosan resulted in higher yields of cell culture products, with the exception of 0.5% chitosan. Important to note here is that the maximum stock concentration of chitosan that can be reached is 2%, due to the viscosity of the solution. Hence, the 0.5% condition would also significantly dilute the cell concentration and thus potentially the yield.

[0096] The optimal concentration range identified with a crustacean derived chitosan was then applied to a vegan derived chitosan (Figure 2B), which resulted in similar CCP yield. As initial experiments were conducted using relatively low viable cell concentrations (VCCs) of 0.9 million cells per millilitre (mL), the conditions were repeated with high VCCs of 44.6 million cells per mL (Figure 2C). Although the yield of CCPs was guite similar with and without addition of chitosan, and between chitosan concentrations at high VCCs, flocculation only occurred in conditions where chitosan was added.

[0097] Initiating efficient levels of flocculation is a key aspect in the elimination of a centrifugation step as a necessary procedure to separate supernatant from CCPs. Flocculation efficiency and yield were dependent on pH of the culture after addition of chitosan, which by itself is already dissolved in an acidic solvent. Any pH higher than 7.3 resulted in the loss of flocculation, indicating that chitosan efficiency is dependent on the pH of the solution (Figure 2D). A pH range of 5-6.5 was then used to evaluate CCP yield, where a pH of 6.5 resulted in the highest CCP yield (Figure 2E). This pH was then taken forward in future experiments.

[0098] These results show the potential of chitosan as an efficient flocculant for CCPs, without using centrifugation as a method of separation.

[0099] 2. Flocculation enhancers can promote flocculation effectiveness

[0100] Due to the chemical properties of biopolymers such as chitosans, it is possible to combine them with other reagents such as but not limited to; dextran sulfate, carboxymethylcellulose (CMC) and calcium chloride (CaCh). Combination of a chitosan and the previously mentioned reagents canresult in more optimised flocculation and increased capturing of CCPs. Firstly, dextran sulfate showed increased CCP yield upon increasing concentration of dextran sulfate (Figure 3A).

[0101] To diminish dextran sulfate costs, the low concentration was implemented in the current procedure and combined with either CMC or CaCh. To identify the concentration range of CMC that can be used to induce flocculation, 0.28 - 140 mg / L of CMC were tested. All concentrations higher than 1.4 mg / L resulted in increased yield and efficient flocculation (Figure 3B).

[0102] Lastly CaCh was introduced at two different concentrations, which resulted in higher yield upon a higher concentration of CaCh (Figure 2C). Calcium on its own is already known for its proaggregation properties, which increased the flocculation capacity of chitosan. For all experiments with enhancers, other parameters such as pH and temperature were kept stable.

[0103] The treatment with each enhancer and chitosan resulted in CCP flocculation and clearance of the supernatant (Figure 3D-F).

[0104] In addition to harvesting cells, the disclosed method also resulted in harvesting secreted proteins, as can be observed in decreased protein content (Figure 2G-H). This shows surprisingly that the disclosed method does not only capture cells, but also proteins that may contribute to the nutritional profile of cultivated meat.

[0105] Materials and methods

[0106] A. Cell culture

[0107] Spontaneously immortalized chicken fibroblast cells (ATCC, CRL-12203) were cultured in proprietary protein-free culture medium in suspension at 41 °C, 30% dissolved oxygen (DO) and pH of 7.2 in bioreactors (Eppendorf BioBLU 50L) or shake flasks (Nalgene, TMO4116). The inoculum ranged between 0.25 - 2 x 106cells / ml, with cell viabilities higher than 85%. Cultures were run in batch or perfusion operation mode, depending on the final viable cell concentration (VCC) required. VCC and cell viability were monitored using a Countess™ Automated Cell Counter (Fisher Scientific)

[0108] B. Preparation of Chitosan

[0109] Vegan chitosan (Biosynth, YC171030) or crustacean chitosan (Sigma Aldrich, 448877-50G) was dissolved in 1% acetic acid solution via vigorous stirring on a stirrer plate, to reach a 2% final concentration. The 1% acetic acid solution was made from pure acetic acid (Fisher Scientific, 10041250) in type II purified water (Milli-Q filtered). The chitosan solution was pasteurised at 60°C for 1 hour, while being stirred.

[0110] C. Adjusting pH to test flocculation efficiencypH of cell culture was measured using the FiveEasy F20 Mettler Toledo Benchtop pH meter. To achieve the desired pH, 0.75M NaOH or 0.1 M HCI were used. pH was measured both before and after adding chitosan to the cell suspension, since chitosan will lower the pH due the acidic nature of its solvent, n The results presented show the pH after the addition of chitosan.

[0111] D. Preparations of Crosslinkers I Binders

[0112] Preparation of carboxymethylcellulose (CMC): CMC powder (Sigma Aldrich, 419338) was steam autoclaved at 121 °C for 15 minutes and then dissolved in filtered type II purified water by vigorous stirring to reach a final concentration of 1.4% (w / v).

[0113] Preparation of calcium chloride: calcium chloride dihydrate (Sigma Aldrich, 223506) was dissolved in filtered type II purified water and then sterilised by filtering through a 0.2um polyethersulfone (PES) filter (Fisher Scientific, 15206869).

[0114] Preparation of dextran sulfate: dextran sulfate sodium salt (Fisher Scientific, J62101.A1) was dissolved in filtered type II purifiedwaterand sterilised by filtering through a 0.2um PES filter (Fisher Scientific, 15206869).

[0115] E. Flocculation of Culture

[0116] Cell culture was harvested when it had reached peak viable cell concentration (VCC) of 1 to 100 x10A6 cells / mL. Chitosan was added directly to the culture to a final concentration of 0.01 - 0.5%. Once chitosan was added and stirred until the mixture was homogeneous, carboxymethylcellulose (CMC) was added, and the mixture was agitated until flocculation occurred and supernatant visibly clarified (5-15 mins).

[0117] For alternative enhancers including calcium chloride, dextran, polyethylene glycol (PEG), polyethylene oxide (PEO), xanthan gum, alginate and citrate, these were added to cell culture to incubate prior to the addition of chitosan. After the addition of chitosan, the mixture was agitated until flocculation occurred, then it was settled until supernatant visibly clarified.

[0118] The CCPs were allowed to separate from the clarified supernatant, which was then removed. F. Analysis of Samples

[0119] The yield was measured by weighing biomass on a calibrated balance (SLS lab Basics Valido Balance).

[0120] Flocculation was measured by observation using a scoring system based on the following parameters: flocculant size, clarity of supernatant, time to reach flocculation and sedimentation of flocculated CCP. This scoring system was determined from 0 (no flocculation) to 10 (perfect, fast flocculation with clear supernatant).

[0121] SDS PAGECell culture samples from three independent bioreactor runs were collected before and after treatment with the harvesting agents. Samples were centrifuged at 3100 g for 5 minutes to retrieve the supernatant and further filtered with a 0.22 microns PES filter. Samples were stored refrigerated (0-5°C) until analysed. To analyse protein content pre- and post-harvest, 40 pl of each supernatant sample were taken. Samples were combined with 5x sample buffer prepared with inhouse reagents: bromophenol blue, dithiothreitol (DTT), glycerol, sodium dodecyl sulphate (SDS),Tris-HCI (1 M stock) and H2O. Then combined samples were heated to 95°C for 5 minutes in a heating block to denature proteins. Afterwards, protein samples were centrifuged briefly. Precast 12 well Bolt Bis Tris plus 4-12% gel (Fisher Scientific, NW04122BOX) was installed inside the gel running tank. Invitrogen™ Novex™ 20x Bolt™ MES SDS running buffer (Fisher Scientific, 13266499) was mixed with water to 1x concentration and added to running tank between the gels. Protein samples were loaded at 40 pl sample per well, alongside with 7 pl of molecular weight standard - PageRuler Prestained protein ladder (Fisher Scientific, 26617). SDS PAGE was run at 200V for 25 minutes. After the run, the gel was stained with Quick Coomassie stain (Generon, GEN-QC-STAIN-3L) for 7 hours on a rotating platform. Water was used to wash away any unbound Coomassie stain from the gel, which was then imaged on Azure 400 Biosystems imager. Imaged software was used for protein quantification.

[0122] Although particular embodiments of the invention have been disclosed herein in detail, this has been done by way of example and for the purposes of illustration only. The aforementioned embodiments are not intended to be limiting with respect to the scope of the appended claims, which follow. It is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims.

[0123] The present invention relates to genetic resources obtained within the United Kingdom. The invention does not utilise or rely upon genetic resources or traditional knowledge obtained from any other country.

Claims

CLAIMS1. A process for the production of an animal cell culture product, the process comprising the steps of:a. culturing animal cells in suspension within a liquid cell culture medium under conditions that promote proliferation until a required cell concentration is attained; b. adding a flocculating agent to the cell culture suspension to initiate flocculation of the cultured animal cells and extracellular protein, so as to form an aggregated cell culture product; andc. recovering the aggregated cell culture product by removing the liquid cell culture medium.

2. The process of claim 1 , wherein the removal of the liquid cell culture medium is via decanting.

3. The process of claims 1 or 2, wherein the removal of the liquid cell culture medium does not involve centrifugation.

4. The process of any one of claims 1 to 3, wherein the flocculating agent comprises a polymer, such as a biopolymer, that has a high cationic charge density.

5. The process of claim 4, wherein the polymer comprises:a biopolymer selected from: a chitosan, a cellulose derivative, a starch-based polymer, or inulin; ora polymer selected from: polyethyleneimine (PEI), or polydiallyldimethylammonium chloride (polyDADMAC).

6. The process of claim 5, wherein the polymer comprises a chitosan, optionally wherein the chitosan is of crustacean, fungal or insect origin.

7. The process of any previous claim, wherein the pH of the cell culture suspension is adjusted to below neutral upon addition of the flocculating agent to the cell culture suspension.

8. The process of any one of claims 1 to 6, wherein the pH of the cell culture suspension is adjusted to not less than 5 and not more than 7.3 upon addition of the flocculating agent to the cell culture suspension.

9. The process of claims 7 or 8, wherein the pH of the cell culture suspension is adjusted to around 6.5.

10. The process of any previous claim, wherein the concentration of the flocculating agent is selected from at least around: 0.01 %w / v; 0.02%w / v; 0.05%w / v; 0.1%w / v; 0.2%w / v; 0.5%w / v; 0.7%w / v; 1%w / v; 1.2%w / v; 1.5%w / v; 1.7%w / v; 2%w / v in the cell culture medium.

11. The process of any previous claim, wherein liquid cell culture medium is a serum free medium.

12. The process of any previous claim, wherein liquid cell culture medium is a protein free medium.

13. The process of any previous claim, wherein a flocculation enhancer is added simultaneously or successively to the step of adding a flocculating agent.

14. The process of claim 13, wherein the flocculation enhancer is selected from: dextran; carboxymethylcellulose (CMC); calcium chloride; polyethylene glycol (PEG); polyethylene oxide (PEO); xanthan gum; alginate and / or citrate.

15. The process of claim 14, wherein the flocculation enhancer comprises:carboxymethylcellulose at a concentration of around 0.28 to around 140 mg / L; and / or dextran sulfate at a concentration of around 30 to around 300 mg / L; and / orcalcium chloride at a concentration of around 0.1 to around 1 mM, in the cell culture medium.

16. The process of any one of claims 13 to 15, wherein the flocculating agent and the flocculation enhancer are premixed to form a flocculation composition before addition to the cell culture suspension.

17. The process of any previous claim, wherein step (a) is carried out within a first bioreactor vessel.

18. The process of claim 17, wherein the cultured animal cells in step (a) are transferred from the first bioreactor vessel to a second biomass harvesting vessel in order to perform step (b).

19. The process of claim 18, wherein the first bioreactor vessel and the second biomass harvesting vessel are in fluid communication with one another.

20. The process of any previous claims, wherein the animal cells are selected from: mammalian cells, avian cells, fish cells, crustacean cells, mollusc, insect or reptile cells.

21. The process of claim 20, whereinthe mammalian cells are selected from: cow, pig, goat, sheep, or deer; orthe avian cells are selected from: chicken, duck, goose, turkey, partridge, grouse, pigeon, guinea fowl, ostrich or quail; orthe fish cells are selected from: salmon, trout, tuna, hake, halibut, haddock, cod, tilapia, Atlantic croaker, swordfish or coley.the crustacean cells are selected from: lobster, crab or shrimp;the mollusc cells are selected from: octopus, squid, cuttlefish, abalone or bivalves such as oyster, mussel, scallop, or clam; orthe reptile cells are selected from: crocodile, alligator or snake.

22. The process of any one of claims 1 to 21 , wherein the aggregated cell culture product comprises a combination of animal cells and extracellular proteins.

23. The process of any one of claims 1 to 22, wherein the animal cell culture product is for use in the production of cultivated meat.

24. The process of any one of claims 1 to 23, wherein the animal cells comprise immortalised fibroblasts.

25. The process of any one of claims 1 to 24, wherein the animal cells comprise cells of myogenic origin, optionally skeletal muscle cells or precursors thereof.

26. The process of claim 25, wherein the cells of myogenic origin are cultured in combination with adipocytes, fibroblasts, and / or endothelial cells.

27. The process of any one of claims 1 to 26, wherein the cell culture is harvested when it has reached a peak viable cell concentration of at least around 1 x 106cells / mL.

28. The process of any one of claims 1 to 26, wherein the cell culture is harvested when it has reached a peak viable cell concentration of at least around 10 x 106cells / mL.

29. The process of any one of claims 1 to 26, wherein the cell culture is harvested when it has reached a peak viable cell concentration of at least around 50 x 106cells / mL.

30. The process of any one of claims 1 to 26, wherein the cell culture is harvested when it has reached a peak viable cell concentration of at least around 100 x 106cells / mL.

31. The process of any one of claims 1 to 30, wherein the flocculation step comprises gentle mixing or agitation to distribute the flocculating agent throughout the cell culture suspension.

32. The process of any one of claims 1 to 30, wherein the aggregated cell culture product is allowed to settle before removal of clarified supernatant.

33. The process of any one of claims 17 to 32, wherein an automated feedback control system is provided to monitor cell density in the first bioreactor vessel and to thereby regulate the transfer rate of cultured animal cells to the second biomass harvesting vessel.

34. The process of any one of claims 1 to 33, comprising a further step comprising subjecting the recovered aggregated cell culture product to dewatering, pasteurisation, preservation or onward processing to create a consumable product.

35. A cell culture product obtainable according to the process of any one of claims 1 to 34.

36. A cell culture product comprising animal cells, extracellular secreted protein and a polymer having a high cationic charge density.

37. The cell culture product of claim 36, wherein the polymer having a high cationic charge density is a chitosan.

38. The cell culture product of claim 37, wherein the chitosan comprises a chitosan of nonanimal origin, optionally a fungal chitosan.

39. The cell culture product of any one of claims 36 to 38, wherein the cell culture product is in the form of a heterogeneous cellular agglomerate or cellular paste.

40. The cell culture product of any one of claims 36 to 39, wherein the cell culture product comprises a solids content of at least 5% wt, at least 10% wt, at least 15% wt, at least 20% wt, or at least 25% wt.

41. The cell culture product of any one of claims 36 to 40, wherein the extracellular secreted protein comprises extracellular matrix components, optionally including proteoglycans and structural glycoproteins.

42. A consumable cultivated meat product comprising the cell culture product of any one of claims 36 to 41.

43. The consumable cultivated meat product of claim 42, wherein the consumable cultivated meat product is for human consumption.

44. The consumable cultivated meat product of claim 42, wherein the consumable cultivated meat product is for animal consumption.

45. The consumable cultivated meat product of any one of claims 42 to 44, wherein the cell culture product is used as an ingredient for a food product.

46. The consumable cultivated meat product of any one of claims 42 to 44, wherein the cell culture product is used as a bioink component for 3D printing.

47. The consumable cultivated meat product of any one of claims 42 to 46, wherein the consumable cultivated meat product is selected from: structured meat products, emulsified meat products, cured meat products, minced meat products, whole-cut analogues, meat-filled dumplings or pastries, dried meat products, smoked meat products, blended hybrid products, ready-to-eat meal components, freeze-dried meat products, sous-vide prepared meat products, marinated meat products, breaded and coated meat products, stuffed meat products, meat spreads or pates, seasoned meat crumbles, restructured meat products, meat-based ingredient preparations, or shelf-stable meat products.

48. The consumable cultivated meat product of any one of claims 42 to 46, wherein the consumable cultivated meat product is selected from: wet canned pet foods, freeze-dried complete pet meals, premium protein kibble coatings, pet food toppers, dried meat treats and chews, frozen raw diet components, therapeutic veterinary diet proteins, soft-moist pet treats, long-lasting dental chews, refrigerated fresh pet foods, specialised life-stage formulations, protein-enriched supplement toppers, liquid nutritional supplements, species-specific exotic proteins, textured meat inclusions for dry foods, meat-based pill pockets, shelf-stable pouched pet foods, zoo animal specialty feeds, aquaculture feed ingredients, reptile and exotic pet food formulations, enrichment treat dispensers, recovery diets for hospitalised animals, breeding stock specialty nutrition, performance animal supplements, or wildlife rehabilitation feed components.

49. Use of a polymer having a high cationic charge density as a flocculating agent for harvesting animal cells and extracellular secreted protein from a suspension culture of animal cells.

50. The use of claim 49, wherein the suspension culture comprises a cultivated meat cell culture.

51. The use of claim 49 or claim 50, wherein the polymer comprises a chitosan, optionally non-animal chitosan, more optionally a fungal derived chitosan.

52. The use of any one of claims 49 to 51 , wherein the harvesting is carried out without centrifugation.